摘要
Objective: To observe the therapeutic effects of Jingyuankang capsules (精元康胶囊) for leukopenia in AIDS patients. Methods: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen tablet and the HAART (highly active anti-retroviral therapy) drugs, and the other 58 patients took Leucogen tablet, analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS patients. Results: With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance leukocyte level as effective as Leucogen tablet in treating grade Ⅰ and grade Ⅱ leukopenia, and more effectively than Leucogen tablet in treating grade Ⅲ leukopenia. No toxic side-effects and adverse reactions were found during the treatment and in the follow-up visit. Conclusion: Jingyuankang capsule can effectively treat leukopenia of the AIDS patients.
Objective： To observe the therapeutic effects of Jingyuankang capsules （精元康胶囊） for leukopenia in AIDS patients. Methods： In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen tablet and the HAART （highly active anti-retroviral therapy） drugs, and the other 58 patients took Leucogen tablet, analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS patients. Results： With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance leukocyte level as effective as Leucogen tablet in treating grade Ⅰ and grade Ⅱ leukopenia, and more effectively than Leucogen tablet in treating grade Ⅲ leukopenia. No toxic side-effects and adverse reactions were found during the treatment and in the follow-up visit. Conclusion： Jingyuankang capsule can effectively treat leukopenia of the AIDS patients.
基金
supported by a grant from the National Key Technology R&D Program of the Ministry of Science and Technology of China (No.2004BA719A09-0203)
